Breaking News Instant updates and real-time market news.

ARE

Alexandria Real Estate

$111.72

-0.4 (-0.36%)

, MRK

Merck

$62.19

0.39 (0.63%)

06:00
11/30/16
11/30
06:00
11/30/16
06:00

Alexandria Real Estate announces built-to-suit lease for Merck research facility

Alexandria Real Estate Equities (ARE) announced that Merck (MRK) has selected Alexandria to develop, construct and operate its new West Coast research facility at 213 East Grand Avenue in the heart of the South San Francisco innovation cluster. Merck executed a long-term, full-building lease for a nine-story, 294,000 rentable square feet laboratory/office campus. The 213 East Grand Avenue campus site is fully entitled, and construction is expected to commence in early 2017. The building, targeted for LEED Platinum certification, is expected to be placed into service in early 2019.

ARE

Alexandria Real Estate

$111.72

-0.4 (-0.36%)

MRK

Merck

$62.19

0.39 (0.63%)

  • 03

    Dec

  • 08

    Mar

ARE Alexandria Real Estate
$111.72

-0.4 (-0.36%)

08/25/16
BTIG
08/25/16
INITIATION
Target $124
BTIG
Buy
Alexandria Real Estate initiated with a Buy at BTIG
BTIG analyst James Sullivan initiated Alexandria Real Estate with a Buy and $124 price target. The analyst expects high occupancy and strong tenant demand to push rents and robust growth of life science and tech companies, and corporate relocations from suburban markets to urban clusters to drive above average SSNOI growth.
MRK Merck
$62.19

0.39 (0.63%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.

TODAY'S FREE FLY STORIES

HSBC

HSBC

$55.39

-0.23 (-0.41%)

06:06
01/19/18
01/19
06:06
01/19/18
06:06
Hot Stocks
HSBC agrees to pay more than $100M to resolve fraud charges »

HSBC Holdings has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$55.60

0.73 (1.33%)

06:03
01/19/18
01/19
06:03
01/19/18
06:03
Recommendations
Atlassian analyst commentary  »

Atlassian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

STI

SunTrust

$67.94

-0.41 (-0.60%)

06:03
01/19/18
01/19
06:03
01/19/18
06:03
Earnings
SunTrust reports Q4 EPS with items $1.48, consensus $1.05 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RF

Regions Financial

$18.15

-0.21 (-1.14%)

06:02
01/19/18
01/19
06:02
01/19/18
06:02
Hot Stocks
Breaking Hot Stocks news story on Regions Financial »

Regions Financial reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RF

Regions Financial

$18.15

-0.21 (-1.14%)

06:02
01/19/18
01/19
06:02
01/19/18
06:02
Hot Stocks
Regions Financial reports Q4 net interest margin 3.32% »

Up 18 basis points, and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RF

Regions Financial

$18.15

-0.21 (-1.14%)

06:00
01/19/18
01/19
06:00
01/19/18
06:00
Earnings
Regions Financial reports Q4 cont ops EPS 27c, consensus 26c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

MWA

Mueller Water

$12.28

-0.06 (-0.49%)

05:59
01/19/18
01/19
05:59
01/19/18
05:59
Downgrade
Mueller Water rating change  »

Cowen downgrades Mueller…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 22

    Feb

OBLN

Obalon Therapeutics

$6.14

-0.725 (-10.56%)

05:57
01/19/18
01/19
05:57
01/19/18
05:57
Syndicate
Obalon Therapeutics 5.455M share Secondary priced at $5.50 »

UBS, Canaccord and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

GDEN

Golden Entertainment

$28.21

-0.6 (-2.08%)

05:56
01/19/18
01/19
05:56
01/19/18
05:56
Syndicate
Golden Entertainment 6.5M share Secondary priced at $28.00 »

JPMorgan and Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AGIO

Agios Pharmaceuticals

$68.15

-2.18 (-3.10%)

05:56
01/19/18
01/19
05:56
01/19/18
05:56
Syndicate
Agios Pharmaceuticals 7.09M share Secondary priced at $67.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

AAPL

Apple

$179.26

0.16 (0.09%)

05:55
01/19/18
01/19
05:55
01/19/18
05:55
Periodicals
S. Korean consumer group files criminal complaint against Apple CEO, CNBC says »

South Korean consumer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

AVT

Avnet

$41.32

-0.33 (-0.79%)

05:54
01/19/18
01/19
05:54
01/19/18
05:54
Upgrade
Avnet rating change  »

Avnet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

FCAU

Fiat Chrysler

$23.40

0.28 (1.21%)

05:54
01/19/18
01/19
05:54
01/19/18
05:54
Upgrade
Fiat Chrysler rating change  »

Fiat Chrysler upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$17.06

0.085 (0.50%)

05:54
01/19/18
01/19
05:54
01/19/18
05:54
Upgrade
Danone rating change  »

Danone upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$45.28

2.31 (5.38%)

05:53
01/19/18
01/19
05:53
01/19/18
05:53
Downgrade
WNS Holdings rating change  »

WNS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$55.35

-2.54 (-4.39%)

05:53
01/19/18
01/19
05:53
01/19/18
05:53
Upgrade
BNY Mellon rating change  »

BNY Mellon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

CRBP

Corbus Pharmaceuticals

$7.95

-0.25 (-3.05%)

05:52
01/19/18
01/19
05:52
01/19/18
05:52
Initiation
Corbus Pharmaceuticals initiated  »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESS

Essex Property Trust

$224.60

-2.76 (-1.21%)

05:49
01/19/18
01/19
05:49
01/19/18
05:49
Downgrade
Essex Property Trust rating change  »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

GPN

Global Payments

, FDC

First Data

$17.56

-0.04 (-0.23%)

05:48
01/19/18
01/19
05:48
01/19/18
05:48
Recommendations
Global Payments, First Data, Worldpay analyst commentary  »

Global Payments price…

GPN

Global Payments

FDC

First Data

$17.56

-0.04 (-0.23%)

WP

Worldpay

$79.08

1.19 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 01

    Mar

MWA

Mueller Water

$12.28

-0.06 (-0.49%)

05:48
01/19/18
01/19
05:48
01/19/18
05:48
Downgrade
Mueller Water rating change  »

Mueller Water downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 22

    Feb

CUB

Cubic

$59.95

-0.8 (-1.32%)

05:48
01/19/18
01/19
05:48
01/19/18
05:48
Downgrade
Cubic rating change  »

Cubic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

VEOEY

Veolia Environment

$25.50

-0.285 (-1.11%)

05:46
01/19/18
01/19
05:46
01/19/18
05:46
Upgrade
Veolia Environment rating change  »

Veolia Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$91.54

-1.33 (-1.43%)

05:45
01/19/18
01/19
05:45
01/19/18
05:45
Upgrade
MAA rating change  »

MAA upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SIEN

Sientra

$10.33

-0.71 (-6.43%)

05:45
01/19/18
01/19
05:45
01/19/18
05:45
Upgrade
Sientra rating change  »

Sientra upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

CMG

Chipotle

$337.53

2.9 (0.87%)

05:43
01/19/18
01/19
05:43
01/19/18
05:43
Upgrade
Chipotle rating change  »

Chipotle upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.